No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
EVGN Evogene
- 0.6151
- -0.0423-6.43%
Close Jun 20 16:00 ET
- 0.6458
- +0.0307+4.99%
Post 18:36 ET
31.16MMarket Cap-1366P/E (TTM)
0.6450High0.6150Low143.79KVolume0.6401Open0.6574Pre Close90.05KTurnover0.31%Turnover RatioLossP/E (Static)50.66MShares1.440052wk High3.75P/B28.71MFloat Cap0.450252wk Low--Dividend TTM46.68MShs Float20.3890Historical High--Div YieldTTM4.56%Amplitude0.4502Historical Low0.6260Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Evogene Innovates With AI in Life-Sciences
Earnings Call Summary | Evogene(EVGN.US) Q1 2024 Earnings Conference
The following is a summary of the Evogene Ltd. (EVGN) Q1 2024 Earnings Call Transcript:Financial Performance:Evogene reported total revenue of approximately $4.2 million in Q1 2024, a significant incr
Express News | Biomica Announces Encouraging Initial Findings From Phase 1 Clinical Trial Of BMC128, Its Microbiome-Based Immuno-Oncology Candidate, In Combination With Nivolumab For Patients With NSCLC, Melanoma, Or RCC
Biomica Presents Positive Clinical Data Update From Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma
Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd....
Lake Street Maintains Evogene(EVGN.US) With Buy Rating, Maintains Target Price $3
Lake Street analyst Ben Klieve maintains $Evogene(EVGN.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 44.9% and a total aver
Evogene's Strategic Growth Boosts Q1 2024 Results
Comments
$Evogene(EVGN.US$
NEWS
Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma
NEWS
Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma
1
Dr. Gelvan's appointment is anticipated to steer AgPlenus towards its next growth phase. His skills in securing funding and managing multicultural teams are seen as a major asset.
$Vertex Energy(VTNR.US$ i dont think this will have much attention but keep it a close watch
$Indonesia Energy(INDO.US$ indo tend to be the most squeeze most hype , could possible 7-9 PT
$Houston American Energy(HUSA.US$ husa usually sympathy play to indo if indo squeeze then husa can go at least 6-7 PT
$Imperial Petroleum(IMPP.US$ this has very high possible squeeze , why i say so? eversince this run 9 and beaten down to penny stock to 0.2-0.3 and keep on dilu...
$Indonesia Energy(INDO.US$ indo tend to be the most squeeze most hype , could possible 7-9 PT
$Houston American Energy(HUSA.US$ husa usually sympathy play to indo if indo squeeze then husa can go at least 6-7 PT
$Imperial Petroleum(IMPP.US$ this has very high possible squeeze , why i say so? eversince this run 9 and beaten down to penny stock to 0.2-0.3 and keep on dilu...
30
14
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg